Abstract
A quantitative analysis of the viral transmission risk in public spaces allows us to identify the dominant mechanisms that a proactive public health policy can act upon to reduce risk, and to evaluate the reduction of risk that can be obtained. The contribution of public spaces to the propagation of SARS-CoV-2 can be reduced to a level necessary for a declining epidemic, i.e. an overall reproduction rate below one. Here, we revisit the quantitative assessment of indoor and outdoor transmission risk. We show that the long-range aerosol transmission is controlled by the flow rate of fresh air and by the mask filtering quality, and is quantitatively related to the CO2 concentration, regardless the room volume and the number of people. The short-range airborne transmission is investigated experimentally using dedicated dispersion experiments performed in two shopping malls. Exhaled aerosols are dispersed by turbulent draughts in a cone, leading to a concentration inversely proportional to the squared distance and to the flow velocity. We show that the average infection dose, called the viral quantum, can be determined from epidemiological data in a manner consistent with biological experimental data. The results provide quantitative guidance useful for making rational public health policy decisions to prevent the dominant routes of viral transmission through reinforced ventilation, air purification, mechanical dispersion using fans, and incentivizing the wearing of correctly fitted, quality facial masks (surgical masks, possibly covered by another fabric mask, or non-medical FFP2 masks). Taken together, such measures significantly reduce the airborne transmission risk of SARS-CoV-2.
Competing Interest Statement
This work was funded by Unibail-Rodamco-Westfield on be- half of Conseil National des Centres Commerciaux (CNCC), who asked the authors to make recommendations for a san- itary protocole aiming to reduce and quantify the transmis- sion risk in shopping centers. The conclusions of the present article are therefore of direct interest for the funding com- pany. The authors declare no financial competing interest. The funding company had no such involvement in study de- sign, in the collection, analysis, and interpretation of data, nor in the writing of the article. The authors had the full respons- ability in the decision to submit it for publication.
Funding Statement
This work was funded by Unibail-Rodamco-Westfield on behalf of Conseil National des Centres Commerciaux (CNCC) under the CNRS contract 217977.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB no ethics committee was necessary.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
No external dataset
